Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
2(17%)
Results Posted
67%(6 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
2
17%
Ph phase_2
4
33%
Ph phase_1
6
50%

Phase Distribution

6

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
6(50.0%)
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
2(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(9)
Terminated(1)

Detailed Status

Completed9
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (50.0%)
Phase 24 (33.3%)
Phase 32 (16.7%)

Trials by Status

active_not_recruiting217%
terminated18%
completed975%

Recent Activity

2 active trials
Showing 5 of 12
active_not_recruitingphase_2

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

NCT00092222
active_not_recruitingphase_1

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

NCT05357482
completedphase_1

Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936
completedphase_1

TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

NCT02043847
completedphase_2

Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants

NCT00378534
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT00092222Phase 2

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Active Not Recruiting
NCT05357482Phase 1

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Active Not Recruiting
NCT03263936Phase 1

Epigenetic Reprogramming in Relapse/Refractory AML

Completed
NCT02043847Phase 1

TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

Completed
NCT00378534Phase 2

Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants

Completed
NCT02043860Phase 1

Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma

Terminated
NCT00002835Phase 3

Combination Chemotherapy in Treating Patients With Lymphoma

Completed
NCT00002836Phase 3

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

Completed
NCT00385788Phase 2

Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

Completed
NCT00450801Phase 2

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Completed
NCT00002837Phase 1

High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer

Completed
NCT00002838Phase 1

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12